292 related articles for article (PubMed ID: 24103633)
21. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
[TBL] [Abstract][Full Text] [Related]
22. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.
Tieu JD; Schmidt SA; Miller JL; Kupiec KE; Skrepnek GH; Liu C; Smith WJ
J Oncol Pharm Pract; 2019 Apr; 25(3):520-528. PubMed ID: 29157145
[TBL] [Abstract][Full Text] [Related]
23. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
24. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
26. Clostridium difficile-associated disease treatment response depends on definition of cure.
Lawrence SJ; Dubberke ER; Johnson S; Gerding DN
Clin Infect Dis; 2007 Dec; 45(12):1648; author reply 1649-51. PubMed ID: 18190331
[No Abstract] [Full Text] [Related]
27. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Tart SB
J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
[TBL] [Abstract][Full Text] [Related]
28. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
[TBL] [Abstract][Full Text] [Related]
29. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
30. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
31. Effect of age on treatment outcomes in Clostridium difficile infection.
Louie TJ; Miller MA; Crook DW; Lentnek A; Bernard L; High KP; Shue YK; Gorbach SL
J Am Geriatr Soc; 2013 Feb; 61(2):222-30. PubMed ID: 23379974
[TBL] [Abstract][Full Text] [Related]
32. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile.
Early CR; Park JM; Dorsch MP; Pogue KT; Hanigan SM
Transpl Infect Dis; 2016 Oct; 18(5):714-720. PubMed ID: 27501504
[TBL] [Abstract][Full Text] [Related]
33. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
[TBL] [Abstract][Full Text] [Related]
34. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.
Le F; Arora V; Shah DN; Salazar M; Palmer HR; Garey KW
Pharmacotherapy; 2012 Feb; 32(2):129-34. PubMed ID: 22392421
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
Louie T; Miller M; Donskey C; Mullane K; Goldstein EJ
Antimicrob Agents Chemother; 2009 Jan; 53(1):223-8. PubMed ID: 18955525
[TBL] [Abstract][Full Text] [Related]
36. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Bishara J; Wattad M; Paul M
Clin Infect Dis; 2007 Dec; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
[No Abstract] [Full Text] [Related]
37. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
39. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
[TBL] [Abstract][Full Text] [Related]
40. Potential protective role of linezolid against Clostridium difficile infection.
Valerio M; Pedromingo M; Muñoz P; Alcalá L; Marin M; Peláez T; Giannella M; Bouza E
Int J Antimicrob Agents; 2012 May; 39(5):414-9. PubMed ID: 22445203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
